Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
…, R Landewé, P Wordsworth, J Wollenhaupt… - The Lancet, 2013 - thelancet.com
Background Ankylosing spondylitis is a chronic immune-mediated inflammatory disease
characterised by spinal inflammation, progressive spinal rigidity, and peripheral arthritis. …
characterised by spinal inflammation, progressive spinal rigidity, and peripheral arthritis. …
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors …
…, R Blanco, C Charles-Schoeman, J Wollenhaupt… - The Lancet, 2013 - thelancet.com
Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic
agent has been identified which is universally and persistently effective in all patients. We …
agent has been identified which is universally and persistently effective in all patients. We …
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double …
…, MK Doyle, R Landewé, EL Matteson, J Wollenhaupt… - The Lancet, 2009 - thelancet.com
Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid
arthritis, but whether use of a different TNFα inhibitor can improve patient response is …
arthritis, but whether use of a different TNFα inhibitor can improve patient response is …
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.
…, J Braun, J Listing, J Wollenhaupt - The Journal of …, 2000 - europepmc.org
Objective To describe indicators of disability and handicap in the 2 major inflammatory
rheumatic diseases rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to estimate the …
rheumatic diseases rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to estimate the …
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week …
Objective To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin
(IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA). Methods 42 patients …
(IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA). Methods 42 patients …
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double‐blind, randomized, placebo‐controlled clinical trial
…, F Behrens, P Jones, J Wollenhaupt… - … : Official Journal of …, 2004 - Wiley Online Library
Objective Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an
oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, …
oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, …
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
…, AO Adebajo, J Wollenhaupt… - Annals of the …, 2014 - ard.bmj.com
Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators.
Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared …
Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared …
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
…, K Kwok, L Wang, R Riese, J Wollenhaupt - Annals of the …, 2017 - ard.bmj.com
Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, …
(RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, …
Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies
Objective. To describe the longterm safety and efficacy profile of tofacitinib in patients with
moderate to severe active rheumatoid arthritis (RA). Methods. Data were pooled from 2 open-…
moderate to severe active rheumatoid arthritis (RA). Methods. Data were pooled from 2 open-…
Abatacept in the treatment of patients with psoriatic arthritis: results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial
…, C Ritchlin, PP Tak, J Wollenhaupt… - Arthritis & …, 2011 - Wiley Online Library
Objective To assess the safety and efficacy of abatacept, a selective T cell costimulation
modulator, in patients with psoriatic arthritis (PsA). Methods In this 6‐month, multicenter, …
modulator, in patients with psoriatic arthritis (PsA). Methods In this 6‐month, multicenter, …